PMC:6640909 / 79482-80053 JSONTXT

{"project":"TEST0","denotations":[{"id":"31100109-81-88-7617","span":{"begin":350,"end":353},"obj":"[\"9485226\"]"},{"id":"31100109-105-112-7618","span":{"begin":461,"end":464},"obj":"[\"21530317\"]"},{"id":"31100109-94-101-7619","span":{"begin":561,"end":564},"obj":"[\"26186889\"]"},{"id":"31100109-99-106-7620","span":{"begin":566,"end":569},"obj":"[\"23109468\"]"}],"text":"Patients at risk of RV failure may benefit from primary pharmacological support to increase myocardial contractility and to decrease PVR using a combination of epinephrine, milrinone and inhaled pulmonary vasodilators [e.g. inhaled nitric oxide (iNO) or/and iloprost]. Observational studies have demonstrated a beneficial effect of iNO therapy [235, 236]. However, iNO did not significantly reduce the incidence of RV failure in a multicentre randomized study [237]. Expert panels concluded that it is reasonable to consider using iNO during LVAD implantation [238, 239]."}

{"project":"MyTest","denotations":[{"id":"31100109-9485226-28905677","span":{"begin":350,"end":353},"obj":"9485226"},{"id":"31100109-21530317-28905678","span":{"begin":461,"end":464},"obj":"21530317"},{"id":"31100109-26186889-28905679","span":{"begin":561,"end":564},"obj":"26186889"},{"id":"31100109-23109468-28905680","span":{"begin":566,"end":569},"obj":"23109468"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Patients at risk of RV failure may benefit from primary pharmacological support to increase myocardial contractility and to decrease PVR using a combination of epinephrine, milrinone and inhaled pulmonary vasodilators [e.g. inhaled nitric oxide (iNO) or/and iloprost]. Observational studies have demonstrated a beneficial effect of iNO therapy [235, 236]. However, iNO did not significantly reduce the incidence of RV failure in a multicentre randomized study [237]. Expert panels concluded that it is reasonable to consider using iNO during LVAD implantation [238, 239]."}

{"project":"0_colil","denotations":[{"id":"31100109-9485226-7617","span":{"begin":350,"end":353},"obj":"9485226"},{"id":"31100109-21530317-7618","span":{"begin":461,"end":464},"obj":"21530317"},{"id":"31100109-26186889-7619","span":{"begin":561,"end":564},"obj":"26186889"},{"id":"31100109-23109468-7620","span":{"begin":566,"end":569},"obj":"23109468"}],"text":"Patients at risk of RV failure may benefit from primary pharmacological support to increase myocardial contractility and to decrease PVR using a combination of epinephrine, milrinone and inhaled pulmonary vasodilators [e.g. inhaled nitric oxide (iNO) or/and iloprost]. Observational studies have demonstrated a beneficial effect of iNO therapy [235, 236]. However, iNO did not significantly reduce the incidence of RV failure in a multicentre randomized study [237]. Expert panels concluded that it is reasonable to consider using iNO during LVAD implantation [238, 239]."}

{"project":"2_test","denotations":[{"id":"31100109-9485226-28905677","span":{"begin":350,"end":353},"obj":"9485226"},{"id":"31100109-21530317-28905678","span":{"begin":461,"end":464},"obj":"21530317"},{"id":"31100109-26186889-28905679","span":{"begin":561,"end":564},"obj":"26186889"},{"id":"31100109-23109468-28905680","span":{"begin":566,"end":569},"obj":"23109468"}],"text":"Patients at risk of RV failure may benefit from primary pharmacological support to increase myocardial contractility and to decrease PVR using a combination of epinephrine, milrinone and inhaled pulmonary vasodilators [e.g. inhaled nitric oxide (iNO) or/and iloprost]. Observational studies have demonstrated a beneficial effect of iNO therapy [235, 236]. However, iNO did not significantly reduce the incidence of RV failure in a multicentre randomized study [237]. Expert panels concluded that it is reasonable to consider using iNO during LVAD implantation [238, 239]."}